Ashley Gallagher, Associate Editor

New study results show that the drugs, which block estrogen production, are more effective for premenopausal and postmenopausal women.

Preliminary research results show that immigrants from Africa have lower rates of CVD and stroke.

Individuals who smoke cigarettes regularly and are yet otherwise healthy, without high blood pressure or type 2 diabetes, are still risking their brain health, new study results show.

Effective pre-exposure prophylaxis limits the additional price that payers should be willing to pay for the pre-exposure prophylaxis, investigators say.

Even after taking cardiovascular risks or vascular brain injury into account, the association remained, study results show.

Results from a clinical trial led by investigators at the National Cancer Institute show that 28 of 42 women with tumors generated a reaction.

Investigators find that a small protein cell glucagon-like peptide-1 (GLP-1) couples the body’s control of blood sugar and BP.

Limited empirical data from new study suggests correlations between obesity and individual SDOH, such as education level, food environment, income, and neighborhood.

Medication can now be used as few as 6 times a year for virologically suppressed adults living with the disease without prior treatments not working or resistance to cabotegravir or rilpivirine.

Faricimab-svoa targets and inhibits 2 disease pathways that drive diabetic macular edema and neovascular or “wet” age-related macular degeneration.

But vaccines do not cause infertility or harm pregnancy chances, Boston University School of Public Health research results show.

The results of a new UCLA-led study show that the pandemic has exacerbated disparities in care, widening inequities.

Gaps in vaccination rates may be related to access and not just distrust and skepticism, investigators from Ohio State University find.

New study results show that of those who tested or were presumed positive for SARS-CoV-2, 44% developed neurological symptoms.

Investigators learned that the degree of response depended on whether an individual has had 1, 2, 3, or 4, exposures through infection, vaccination, or both.

Data from 4 analyses show that individuals treated with the drug achieved non-inferior vision gains compared with aflibercept.

Both data sets confirm previously announced results showing that the boost protects against the variant.

Investigators say that the post-acute sequalae markers are Epstein-Barr virus (EBV) DNA levels in the blood, pre-existing types 2 diabetes, the presence of certain antibodies, and SARS-CoV-2 RNA levels in the blood.

Investigators analyzed data to determine the outcomes and risk factors for severe cases and how individuals with inflammatory bowel disease are affected.

New study results show that there are more incidences of this inflammation of the heart muscle related to not being vaccinated than there are to the vaccine itself.

The results of a new analysis show that just 12 to 14 doses of stimulation for the body and mind may be all that is needed to boost brain function.

Stanford Medicine investigators were able to estimate who is most likely to land in the hospital.

Results of an analysis show that 3 doses of either Oxford/AstraZeneca COVID-19 or Pfizer BioNTech COVID-19 neutralizes the variant.

In a presidential advisory, the American Heart Association says that individuals thought to be having an allergic response to the injection may instead by experiencing a cardiac reaction.

Study results demonstrate that ProBiotix’s probiotic strain can significantly reduce low-density lipoprotein levels.

The meta-analysis is the first-of-its-kind phase 3 randomized clinical trial with individual patient data.

A sizable number of clinical trial participants say they had at least 1 AE, with fatigue and headaches the most common.

The analysis describes cost-effective options for individuals without symptoms and recommends isolation strategies to help policymakers safeguard against resurgences.

One viral protein could provide information to deter pneumonia causing the body’s exaggerated inflammatory response, new study results show.

Results from multiple studies show that the effectiveness of nirmatrelvir, the active main protease inhibitor of Paxlovid is maintained.